A phase II study of RO4929097 in metastatic colorectal cancer

Jonathan Strosberg(Moffitt Cancer Center), Timothy J. Yeatman(Moffitt Cancer Center), Jill Weber(Moffitt Cancer Center), Domenico Coppola(Moffitt Cancer Center), Michael J. Schell(Moffitt Cancer Center), Gang Han(Moffitt Cancer Center), Khaldoun Almhanna(Moffitt Cancer Center), Richard D. Kim(Moffitt Cancer Center), Tiffany Valone(Moffitt Cancer Center), Helen Jump(Moffitt Cancer Center), Dan M. Sullivan(Moffitt Cancer Center)

European Journal of Cancer

March 23, 2012

10.1016/j.ejca.2012.02.056

Cited by 147

Abstract

Related Papers

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic, Elizabeth J. Carey, Nina J. Karlin|Breast Care|2013|4.4k

High Performance of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer

Pepijn Brocken, Henricus F.M. van der Heijden, P.N.R. Dekhuijzen et al.|Respiration|2013|4k

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al.|New England Journal of Medicine|2009|3.9k

Notch signalling: a simple pathway becomes complex

Sarah J. Bray|Nature Reviews Molecular Cell Biology|2006|2.6k

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al.|Journal of Clinical Oncology|2007|2k